Retinopathy of Prematurity Market Driven by Rising Preterm Births and Advancements in Treatment

✅ Retinopathy of Prematurity Market: Rising Incidence of Premature Births Fuels Demand for Advanced Treatments

The Retinopathy of Prematurity (ROP) Market is gaining significant traction owing to the increasing number of premature births worldwide and heightened awareness among healthcare providers and parents regarding early screening and treatment. ROP is a potentially blinding eye disorder primarily affecting premature infants born before 31 weeks of gestation. The global market for ROP is poised to grow steadily, driven by rising neonatal care infrastructure, technological advancements in ophthalmic imaging, and strategic initiatives by government and private healthcare entities to improve pediatric eye health.

In 2025, the global ROP market is estimated to be valued at US$ 580.4 million, and it is projected to reach approximately US$ 878.9 million by 2032, growing at a CAGR of 6.1% during the forecast period. The treatment devices segment, particularly laser therapy equipment, dominates the product type segment due to its effectiveness in halting abnormal blood vessel growth. North America leads the global market, driven by a robust healthcare system, early diagnosis capabilities, and high awareness levels among parents and caregivers about neonatal ocular health.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/31397

✅ Key Highlights from the Report

➤The ROP market is projected to reach US$ 878.9 million by 2032.
➤North America is the leading regional market due to advanced neonatal care infrastructure.
➤Laser therapy remains the most commonly used treatment for advanced-stage ROP.
➤Hospitals are the primary end-users, accounting for a major revenue share.
➤Increasing incidence of premature births is a major growth driver.
➤Strategic collaborations and funding initiatives are shaping the future of ROP care.

✅ Frequently Searched Question

What are the current treatment options for Retinopathy of Prematurity (ROP)?

The treatment options for Retinopathy of Prematurity (ROP) are primarily aimed at stopping the abnormal growth of retinal blood vessels, which can lead to vision impairment or blindness. The most commonly used method is laser photocoagulation, which involves using a laser to burn and seal off the peripheral areas of the retina that are not receiving enough oxygen. This helps to stop the abnormal vessel growth. Another method gaining popularity is anti-VEGF (vascular endothelial growth factor) therapy, where medications like bevacizumab are injected into the eye to block the growth signals sent to abnormal blood vessels. Cryotherapy is also occasionally used, although less frequently today, as it tends to cause more retinal damage than laser treatment. In more severe cases or where these therapies fail, vitrectomy or scleral buckling surgery may be performed. Early diagnosis through retinal screening plays a crucial role in the success of these treatments, emphasizing the need for regular eye exams in premature infants.

✅ Market Segmentation

The Retinopathy of Prematurity market can be segmented by treatment type, including laser therapy, anti-VEGF drugs, and surgery. Among these, laser therapy holds the highest share due to its established success in stopping retinal detachment progression. Anti-VEGF injections are rapidly gaining popularity due to their less invasive nature and potential for fewer side effects, especially for infants in early-stage ROP.

By end-user, the market is segmented into hospitals, ambulatory surgical centers (ASCs), and specialized eye clinics. Hospitals account for the largest share due to their access to advanced neonatal intensive care units (NICUs) and trained ophthalmologists. However, the market share of specialized eye clinics is expected to grow as outpatient care becomes more popular and efficient with technological advancements.

✅ Regional Insights

North America dominates the ROP market due to the high survival rate of preterm infants, availability of advanced neonatal and ophthalmic care, and increased parental awareness regarding eye health. The presence of major healthcare facilities and robust reimbursement systems also contribute to the region's leadership.

Asia Pacific, on the other hand, is witnessing the fastest growth due to a sharp increase in premature births, growing healthcare investments, and awareness campaigns launched in countries like India and China. However, accessibility to timely treatment still remains a challenge in rural areas.

✅ Market Drivers, Restraints, and Opportunities

Market Drivers:

A significant driver of the market is the rising incidence of premature births globally. According to the WHO, approximately 15 million babies are born prematurely each year, and a substantial portion are at risk of developing ROP. Additionally, improved survival rates of neonates due to advancements in NICU care have increased the at-risk population. Early screening protocols, improved diagnostic tools like retinal imaging, and availability of trained personnel further drive the demand.

Market Restraints:

One of the major restraints in the market is the lack of access to timely diagnosis and treatment in developing countries. ROP requires early and specialized care, which is not always available in low-income regions. The high cost of equipment and procedures, coupled with insufficient training of pediatric ophthalmologists, limits adoption in some geographies.

Market Opportunities:

There is a growing opportunity in tele-ophthalmology and AI-based retinal screening systems, which can enable early diagnosis even in remote areas. Startups and health tech companies are developing affordable retinal cameras and cloud-based diagnostic tools to help NICUs and eye care providers screen infants effectively. These technological advancements are expected to expand the reach of ROP care in underdeveloped regions.

✅ Reasons to Buy the Report

☑Gain a comprehensive understanding of current and future market trends
☑Access detailed segmentation analysis by product type and end-user
☑Stay updated with regional insights and market dynamics across major geographies
☑Identify key growth opportunities and strategic investment avenues
☑Track competitive developments and innovation in the treatment landscape

✅ Company Insights

✦Novartis AG
✦Regeneron Pharmaceuticals
✦Pfizer Inc.
✦Clarity Medical Systems
✦Retina-AI Health Inc.
✦Phoenix Technology Group
✦Neonatal Care Academy
✦Carl Zeiss Meditec AG

■In June 2025, Clarity Medical Systems announced the launch of an upgraded digital imaging system for neonatal ROP diagnosis with cloud integration for remote screening.

■In March 2025, Regeneron expanded its clinical trial phase for the use of Eylea (aflibercept) in treating advanced stages of ROP, indicating strong focus on pediatric ophthalmology.

✅ Conclusion

The Retinopathy of Prematurity market is undergoing dynamic transformation due to rising premature birth rates, increasing awareness, and significant improvements in neonatal and ophthalmic technologies. With North America leading the market and Asia Pacific emerging rapidly, healthcare stakeholders must invest in robust screening programs and accessible treatment modalities. Innovations in AI-based diagnostics, non-invasive therapies, and global health initiatives are expected to shape the future of this critical pediatric condition. For companies and healthcare providers, staying ahead in this space means leveraging innovation, improving accessibility, and fostering partnerships that prioritize early intervention and child vision care.

✅About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.